Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197336 | 1.00 | MMP13 (0.41) | MMP13ALDH1A1FFAR1FFAR4SMN1; SMN2 | |
| SCHEMBL6194562 | 0.89 | MMP13 (0.43) | MMP13FFAR1FFAR4SLC22A8 | |
| SCHEMBL6192801 | 0.89 | MMP13 (0.43) | MMP13FFAR1FFAR4SLC22A8 | |
| SCHEMBL6192746 | 0.88 | MMP13 (0.52) | MMP13FFAR1FFAR4 | |
| SCHEMBL6194093 | 0.88 | MMP13 (0.43) | MMP13FFAR1FFAR4SLC22A8 | |
| SCHEMBL6190914 | 0.88 | MMP13 (0.52) | MMP13FFAR1FFAR4 | |
| SCHEMBL6212808 | 0.88 | MMP13 (0.43) | MMP13FFAR1FFAR4SLC22A8 | |
| SCHEMBL6838408 | 0.86 | MMP13 (0.40) | MMP13 | |
| SCHEMBL6197340 | 0.86 | MMP13 (0.40) | MMP13 | |
| SCHEMBL6212049 | 0.85 | MMP13 (0.42) | MMP13ALDH1A1FFAR1FFAR4SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539163-A1 | 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014377-A1 | 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | MMP13 3/4885ALDH1A1 1588/4885FFAR1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.